PARTNERING with amzell - making good drugs work better

---

Amzell is seeking out-licensing partners for the commercialization of the products under development.

Amzell’s partnership model values internal and external innovation and expertise as the cornerstone of current and future collaborations. Amzell is therefore constantly looking for new drug delivery technologies and innovative product opportunities from academia and industrial partners to reposition or repurpose well-proven existing active ingredients.

Amzell leverages the benefits offered by regulatory pathways such as 505(b)(2) or orphan drug designation, when applicable, to provide an accelerated path to approval and/or the prospect of exclusivity, through a cost-effective and commercially attractive route.

Partnering and licensing are at the forefront of Amzell’s strategy. Amzell’s existing pipeline portfolio is the result of in-licensing agreements.

Amzell's success is based on increasing the value proposition progressing through the product development along the value chain towards product marketing authorization.

Because of Amzell's lean structure, virtual model and broad expertise, the company can move quickly and cost effectively to provide innovative new products.

---